Literature DB >> 10528110

Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies.

K Arima1, S Hirai, N Sunohara, K Aoto, Y Izumiyama, K Uéda, K Ikeda, M Kawai.   

Abstract

The precursor of the non-Abeta-component of Alzheimer's disease (AD) amyloid (NACP, alpha-synuclein) aggregates into insoluble filaments of Lewy bodies (LBs) in Parkinson's disease (PD) and dementia with LBs (DLB). The microtubule-associated protein tau is an integral component of filaments of neurofibrillary tangles (NFTs). NFTs are occasionally found in brains of PD and DLB; however, the presence of NFTs or tau-epitopes within LB-containing neurons is rare. Double-immunofluorescence study and peroxidase-immunohistochemical study in serial sections, performed to examine the co-localization of tau- and NACP-epitopes in the brainstem of PD and DLB, demonstrated that four different epitopes of tau including phosphorylation-dependent and independent ones were present in a minority of LBs, but more often than previously considered. A tau (tau2)-epitope was localized to filaments in the outer layers of brainstem-type LBs by immunoelectron microscopy. Therefore, we conclude that tau is incorporated into filaments in certain LBs. Extensive investigation has enabled us to classify this co-localization into four types: type 1, LBs with ring-shaped tau-immunoreactivity; type 2, LBs surrounded by NFTs; type 3, NACP- and tau-immunoreactive filamentous and granular masses; and type 4, NACP- and tau-immunoreactive dystrophic neurites. This study raises a new question whether aggregation and hyperphosphorylation of tau in PD and DLB are triggered by the collapse of intraneuronal organization of microtubules due to NACP-filament aggregation in neuronal perikarya and axons.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10528110     DOI: 10.1016/s0006-8993(99)01848-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  50 in total

1.  CSF markers of neurodegeneration in Parkinson's disease.

Authors:  Hana Přikrylová Vranová; Jan Mareš; Martin Nevrlý; David Stejskal; Jana Zapletalová; Petr Hluštík; Petr Kaňovský
Journal:  J Neural Transm (Vienna)       Date:  2010-08-21       Impact factor: 3.575

2.  Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum.

Authors:  R Pattarini; Y Rong; C Qu; J I Morgan
Journal:  Neuroscience       Date:  2008-07-08       Impact factor: 3.590

3.  Do interactions between SNCA, MAPT, and LRRK2 genes contribute to Parkinson's disease susceptibility?

Authors:  Joanna M Biernacka; Sebastian M Armasu; Julie M Cunningham; J Eric Ahlskog; Sun Ju Chung; Demetrius M Maraganore
Journal:  Parkinsonism Relat Disord       Date:  2011-08-03       Impact factor: 4.891

4.  Secondary RNA structure and nucleotide specificity contribute to internal initiation mediated by the human tau 5' leader.

Authors:  Bethany L Veo; Leslie A Krushel
Journal:  RNA Biol       Date:  2012-09-20       Impact factor: 4.652

Review 5.  What can biomarkers tell us about cognition in Parkinson's disease?

Authors:  Brit Mollenhauer; Lynn Rochester; Alice Chen-Plotkin; David Brooks
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

6.  Parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and alpha-synuclein mutations promote Tau protein phosphorylation at Ser262 and destabilize microtubule cytoskeleton in vitro.

Authors:  Hamid Y Qureshi; Hemant K Paudel
Journal:  J Biol Chem       Date:  2010-12-02       Impact factor: 5.157

7.  Tau and alpha-synuclein pathology in amygdala of Parkinsonism-dementia complex patients of Guam.

Authors:  Mark S Forman; M Luise Schmidt; Sanjay Kasturi; Daniel P Perl; Virginia M-Y Lee; John Q Trojanowski
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

8.  Structural basis of the interplay between α-synuclein and Tau in regulating pathological amyloid aggregation.

Authors:  Jinxia Lu; Shengnan Zhang; Xiaojuan Ma; Chunyu Jia; Zhenying Liu; Chengan Huang; Cong Liu; Dan Li
Journal:  J Biol Chem       Date:  2020-04-13       Impact factor: 5.157

Review 9.  Interactions Between α-Synuclein and Tau Protein: Implications to Neurodegenerative Disorders.

Authors:  Xuling Li; Simon James; Peng Lei
Journal:  J Mol Neurosci       Date:  2016-09-15       Impact factor: 3.444

Review 10.  Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.

Authors:  Elvira Valera; Brian Spencer; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.